Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sepideh, Attal"'
Autor:
Sepideh Attal
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 4, Pp 815-817 (2024)
Externí odkaz:
https://doaj.org/article/e2e8e02e3c8a495f93c340364ec90537
Publikováno v:
Cardiology and Therapy, Vol 13, Iss 2, Pp 369-378 (2024)
Abstract Introduction Tafamidis is the first drug approved by the European Commission for the treatment of wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related
Externí odkaz:
https://doaj.org/article/b41fef91209b4a70bfc1a7d61417730e
Autor:
George Koutitas, Kimberly Nolen, Sepideh Attal, Anastasios Ventouris, Yinnon Dolev, Hans Thijs Van Den Broek
Publikováno v:
IEEE Access, Vol 11, Pp 84430-84439 (2023)
Wild-type transthyretin amyloid cardiomyopathy is an under-recognized cause of heart failure. Pfizer previously developed a machine learning model that performed well in identifying wild-type transthyretin amyloid cardiomyopathy vs. nonamyloid heart
Externí odkaz:
https://doaj.org/article/97ce96d8b0f2479b93fcc8a806c63da8
Autor:
Attal, Sepideh1 (AUTHOR) sepideh.attal@pfizer.com
Publikováno v:
Cardiology & Therapy. Dec2024, Vol. 13 Issue 4, p815-817. 3p.
Autor:
Marc Trossaert, Ségolène Claeyssens-Donadel, Thierry Lambert, Chantal Rothschild, Annie Borel-Derlon, Sepideh Attal, Fabienne Volot
Publikováno v:
Transfusion. 57:1066-1071
BACKGROUND Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007. STUDY DESIGN AND METHODS This postmarketing study, as reco
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4953d682054d92ce896b31329fb0ab3b
https://doi.org/10.1111/trf.13988
https://doi.org/10.1111/trf.13988
Autor:
Paul Balmer, Ralf Sprenger, Dina Christopoulou, Tin Tin Htar Myint, Damianos Menegas, Eric Bonnet, Sepideh Attal, Harish Madhava
Publikováno v:
Advances in Therapy. 30:127-151
Streptococcus pneumoniae can cause invasive pneumococcal diseases (IPD), such as bacteremic pneumonia, bacteremia, meningitis, and sepsis, and non-IPDs, such as otitis media, nonbacteremic pneumonia, and upper respiratory tract infections. It was est
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3ed75bdc9d54903305df401ed99b1f8
https://doi.org/10.1007/s12325-013-0007-6
https://doi.org/10.1007/s12325-013-0007-6
Autor:
Thierry, Lambert, Chantal, Rothschild, Fabienne, Volot, Annie, Borel-Derlon, Marc, Trossaërt, Ségolène, Claeyssens-Donadel, Sepideh, Attal
Publikováno v:
Transfusion. 57(4)
Nonacog alfa, the recombinant Factor IX (F IX) used for the treatment of hemophilia B, was approved in Europe in 1998. A reformulated version was approved for European use in 2007.This postmarketing study, as recommended by the risk management plan,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e8288b02f0cd831f7256dfa3e1ddc897
https://pubmed.ncbi.nlm.nih.gov/28337764
https://pubmed.ncbi.nlm.nih.gov/28337764
Autor:
Attal, Sepideh1 (AUTHOR) sepideh.attal@pfizer.com, Kemner, Jason2 (AUTHOR), Alvir, Jose2 (AUTHOR), Barth, Sebastian3 (AUTHOR), Schuessler, Sofia3 (AUTHOR)
Publikováno v:
Cardiology & Therapy. Jun2024, Vol. 13 Issue 2, p369-378. 10p.
Autor:
Lambert, Thierry, Rothschild, Chantal, Volot, Fabienne, Borel ‐ Derlon, Annie, Trossaërt, Marc, Claeyssens ‐ Donadel, Ségolène, Attal, Sepideh
Publikováno v:
Transfusion; Apr2017, Vol. 57 Issue 4, p1066-1071, 6p
Autor:
Myint, Tin, Madhava, Harish, Balmer, Paul, Christopoulou, Dina, Attal, Sepideh, Menegas, Damianos, Sprenger, Ralf, Bonnet, Eric
Publikováno v:
Advances in Therapy; Feb2013, Vol. 30 Issue 2, p127-151, 25p